Introduction
Light-chain amyloidosis (AL amyloidosis) results from extra cellular deposition of fibril-forming monoclonal immunoglobulin light chains. Among these fiber deposition-related organ disorders, renal lesions (amyloid nephropathy) are observed in 50~80% of patients [1] . Prognosis of AL amyloidosis is poor if untreated and is affected by the nature, number, extent of organ involvement, and the presence of concurrent myeloma [2] . To date, there is no established treatment for systemic AL amyloidosis. Conventional chemotherapy with melphalan and dexamethasone induces at least partial hematologic response in approximately 60% of patients. Recently, high-dose melphalan and hematopoietic cell transplantation (HDM/HCT) therapy has emerged as a first line treatment for AL amyloidosis [3] [4] [5] .
However, clinical evidence for this therapy was mostly based on retrospective analyses and randomized controlled trials on this issue are scarce. Herein, we report a case of AL amyloidosis presented with nephrotic syndrome and clinically remitted after HDM/HCT.
Case
A 51-year-old woman visited our hospital due to generalized edema. The patient gained weight 5 kg during the last one month. Her medical history was not remarkable. Blood pressure was 109/82 mmHg, and pitting edema in both low extremities was observed on physical examination. Primary amyloidosis has unfavorable prognosis, particularly with organ involvement. Here, we report a case of clinical remission of renal amyloidosis after autologous hematopoietic cell transplantation. A 51-year-old female patient visited our hospital due to generalized edema. Initial evaluation showed hyperlipidemia, hypoalbuminemia, and heavy proteinuria, which were consistent with nephrotic syndrome. However, IgM lamda type monoclonal gammopathy was detected in serum and urine electrophoresis studies. Renal biopsy showed Congo red-positive amyloid deposition in mesangial area, glomerular capillary walls, and arterioles and amyloid fibers were confirmed by electron microscopy. Immunohistochemial study of the biopsy tissue demonstrated systemic light-chain amyloidosis (AL amyloidosis). Multiple myeloma was not evident on bone marrow examination. She received autologous hematopoietic cell transplantation after high dose melphalan treatment. Complete remissions were achieved after the treatment, respectively. Our findings suggest the potential role of autologous peripheral blood stem cell transplantation in treatment of AL amyloidosis. Spot urine protein creatinine ratio (UPCR) and 24 hour urinary protein excretion were 7.79 g/g, and 6.95 g/day, respectively. Other serologic tests for hepatitis B and C, human immunodeficiency virus, antinuclear antibody and antineutrophil cytoplasmic antibody were negative, and serum complement levels were within the reference range. No cardiomegaly or hepatomegaly was seen on imaging studies. On echocardiography, there was no enhancement of echogenicity in cardiac walls with preserved ejection fraction. Esophago gastro duodenoscopic and colonoscopic findings were not remarkable. Renal biopsy was performed 7 days after the initial evaluation (Fig. 1) . On light microscopy, amorphous periodic acid Schiff positive deposits were observed in the glomerular capillary walls, mesangial area in glomeruli and arterioles. These materials showed an apple Contrary to hematologic response, nephrotic range proteinuria was decreased by 50% from the baseline value at 9 month and amount of proteinuria was normalized 17 months after HDM/ HCT. A second renal biopsy was performed 25 months after the treatment. Congo red positive materials were substantially decreased compared to the initial biopsy findings. However, amyloid deposits remained in the subendothelial area of the glomerulus (Fig. 2) . Spot UPCR at the last visit was 0.26 g/g.
She has been in clinical remission for 28 months.
Discussion
Primary AL amyloidosis is a rare systemic disorder and its clinical features are attributed to deposition of proteins derived from immunoglobulin light chain fragments in various organs such as kidney, heart, and liver. In particular, renal manifestations include asymptomatic proteinuria, nephrotic syndrome, to 12 months in patients who received no treatment or colchicine therapy alone [7, 8] . Although experiences of bone marrow transplantation for treatment of AL amyloidosis were occasionally reported in the mid 1990's, the feasibility and efficacy of HDM/ HCT was first suggested in 1998 by Ray Comenzo and colleagues [9] . Since then, many studies using the same treatment strategy have been reported. It was reported that hematological response rate was more than 60%, complete response rate and a median survival were around 40% and 4.5 years, respectively, after HDM/HCT treatment [5] . However, HDM/HCT in AL amyloidosis still remains restricted to selection of patients; generally younger than 65 years and with localized involvement less than two organs without advanced cardiac amyloidosis.
Despite complete hematologic remission and disappearance of urine M protein and proteinuria, renal histology showed that amyloid deposits remained in the subendothelial area of the glomerulus in this patient. Previous reports also demonstrated that renal amyloid depositions were not regressed even in patients showing complete remission of AL amyloidosis after successful HDM/HCT. It suggested that light chain rather than renal amyloid deposition may induce glomerular injury and increase in protein permeability in glomerulus, consequently [10] .
However, careful follow up is still necessary to confirm the significance of amyloid deposition in glomerulus.
In this report, we described a case of AL amyloidosis, which presented with nephrotic syndrome and improved after HDM/ HCT.
